Chronic myeloid leukemia following chemotherapy with 5′-deoxy-5-fluorouridine for gastric cancer

Motohiro Tsuzuki; Kousuke Handa; Kiyoko Yamamoto; Akio Hasegawa; Yukiya Yamamoto; Masato Watanabe; Syuichi Mizuta; Fumio Maruyama; Masataka Okamoto; Nobuhiko Emi; Kohji Ezaki

doi:10.2169/internalmedicine.47.1072

Chronic myeloid leukemia following chemotherapy with 5′-deoxy-5-fluorouridine for gastric cancer

Motohiro Tsuzuki, Kousuke Handa, Kiyoko Yamamoto, Akio Hasegawa, Yukiya Yamamoto, Masato Watanabe, Syuichi Mizuta, Fumio Maruyama, Masataka Okamoto, Nobuhiko Emi, Kohji Ezaki

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

We report here a very rare case of chronic myeloid leukemia (CML) following long-term chemotherapy with 5′-deoxy-5-fluorouridine (5′-DFUR) for gastric cancer. A 69-year-old man was diagnosed with the chronic phase of CML. Six years previously, he underwent radical subtotal gastrectomy for gastric cancer, and was subsequently treated with oral anti-metabolite 5′-DFUR as adjuvant chemotherapy for 6 years. He was placed on imatinib therapy, and achieved a major molecular response 10 months after the initiation of therapy. This is the first reported case of therapy-related CML following 5′-DFUR treatment.

Original language	English
Pages (from-to)	1739-1741
Number of pages	3
Journal	Internal Medicine
Volume	47
Issue number	19
DOIs	https://doi.org/10.2169/internalmedicine.47.1072
Publication status	Published - 2008
Externally published	Yes

All Science Journal Classification (ASJC) codes

Internal Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2169/internalmedicine.47.1072

Cite this

@article{463bf753e0e14b2f8252f10bec9f9a55,

title = "Chronic myeloid leukemia following chemotherapy with 5′-deoxy-5-fluorouridine for gastric cancer",

abstract = "We report here a very rare case of chronic myeloid leukemia (CML) following long-term chemotherapy with 5′-deoxy-5-fluorouridine (5′-DFUR) for gastric cancer. A 69-year-old man was diagnosed with the chronic phase of CML. Six years previously, he underwent radical subtotal gastrectomy for gastric cancer, and was subsequently treated with oral anti-metabolite 5′-DFUR as adjuvant chemotherapy for 6 years. He was placed on imatinib therapy, and achieved a major molecular response 10 months after the initiation of therapy. This is the first reported case of therapy-related CML following 5′-DFUR treatment.",

author = "Motohiro Tsuzuki and Kousuke Handa and Kiyoko Yamamoto and Akio Hasegawa and Yukiya Yamamoto and Masato Watanabe and Syuichi Mizuta and Fumio Maruyama and Masataka Okamoto and Nobuhiko Emi and Kohji Ezaki",

year = "2008",

doi = "10.2169/internalmedicine.47.1072",

language = "English",

volume = "47",

pages = "1739--1741",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "19",

}

TY - JOUR

T1 - Chronic myeloid leukemia following chemotherapy with 5′-deoxy-5-fluorouridine for gastric cancer

AU - Tsuzuki, Motohiro

AU - Handa, Kousuke

AU - Yamamoto, Kiyoko

AU - Hasegawa, Akio

AU - Yamamoto, Yukiya

AU - Watanabe, Masato

AU - Mizuta, Syuichi

AU - Maruyama, Fumio

AU - Okamoto, Masataka

AU - Emi, Nobuhiko

AU - Ezaki, Kohji

PY - 2008

Y1 - 2008

N2 - We report here a very rare case of chronic myeloid leukemia (CML) following long-term chemotherapy with 5′-deoxy-5-fluorouridine (5′-DFUR) for gastric cancer. A 69-year-old man was diagnosed with the chronic phase of CML. Six years previously, he underwent radical subtotal gastrectomy for gastric cancer, and was subsequently treated with oral anti-metabolite 5′-DFUR as adjuvant chemotherapy for 6 years. He was placed on imatinib therapy, and achieved a major molecular response 10 months after the initiation of therapy. This is the first reported case of therapy-related CML following 5′-DFUR treatment.

AB - We report here a very rare case of chronic myeloid leukemia (CML) following long-term chemotherapy with 5′-deoxy-5-fluorouridine (5′-DFUR) for gastric cancer. A 69-year-old man was diagnosed with the chronic phase of CML. Six years previously, he underwent radical subtotal gastrectomy for gastric cancer, and was subsequently treated with oral anti-metabolite 5′-DFUR as adjuvant chemotherapy for 6 years. He was placed on imatinib therapy, and achieved a major molecular response 10 months after the initiation of therapy. This is the first reported case of therapy-related CML following 5′-DFUR treatment.

UR - https://www.scopus.com/pages/publications/56349110929

UR - https://www.scopus.com/inward/citedby.url?scp=56349110929&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.47.1072

DO - 10.2169/internalmedicine.47.1072

M3 - Article

C2 - 18827427

AN - SCOPUS:56349110929

SN - 0918-2918

VL - 47

SP - 1739

EP - 1741

JO - Internal Medicine

JF - Internal Medicine

IS - 19

ER -

Chronic myeloid leukemia following chemotherapy with 5′-deoxy-5-fluorouridine for gastric cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this